Based on the ImmuCell Corporation stock forecast from 0 analysts, the average analyst target price for ImmuCell Corporation is not available over the next 12 months. ImmuCell Corporation’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ImmuCell Corporation is Slightly Bearish, which is based on 5 positive signals and 7 negative signals. At the last closing, ImmuCell Corporation’s stock price was USD 5.50. ImmuCell Corporation’s stock price has changed by +0.00% over the past week, +11.34% over the past month and +9.13% over the last year.
No recent analyst target price found for ImmuCell Corporation
No recent average analyst rating found for ImmuCell Corporation
Company Overview ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. Read Less
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First D...Read More
Frequently Asked Questions About ImmuCell Corporation (ICCC) Stock
Stock Target Advisor's fundamental analysis for ImmuCell Corporation's stock is Slightly Bearish.
Unfortunately we do not have enough data on ICCC's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ICCC's stock to indicate what its average analyst target is.
ICCC stock's Price/Earning ratio is 170.25.
Our analysis grades ICCC stock's Price / Earning ratio at F. This means that ICCC stock's Price/Earning ratio is above 93% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ICCC may be a overvalued for its sector.
The last closing price of ICCC's stock was USD 5.50.
The most recent market capitalization for ICCC is USD 0.05B.
Unfortunately we do not have enough analyst data on ICCC's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ImmuCell Corporation's stock.
As per our most recent records ImmuCell Corporation has 69 Employees.
ImmuCell Corporation's registered address is 56 Evergreen Drive, Portland, ME, United States, 04103.
You can get more information about it from ImmuCell Corporation's website at https://immucell.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About ImmuCell Corporation (ICCC) Stock
Stock Target Advisor's fundamental analysis for ImmuCell Corporation's stock is Slightly Bearish.
Unfortunately we do not have enough data on ICCC's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ICCC's stock to indicate what its average analyst target is.
ICCC stock's Price/Earning ratio is 170.25.
Our analysis grades ICCC stock's Price / Earning ratio at F. This means that ICCC stock's Price/Earning ratio is above 93% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ICCC may be a overvalued for its sector.
The last closing price of ICCC's stock was USD 5.50.
The most recent market capitalization for ICCC is USD 0.05B.
Unfortunately we do not have enough analyst data on ICCC's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ImmuCell Corporation's stock.
As per our most recent records ImmuCell Corporation has 69 Employees.
ImmuCell Corporation's registered address is 56 Evergreen Drive, Portland, ME, United States, 04103.
You can get more information about it from ImmuCell Corporation's website at https://immucell.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ICCC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
